SEOM Clinical Guideline of management of soft-tissue sarcoma (2020)
Por:
Ferre, AD, Alvarez, RA, Herraez, AC, Jurado, JC, Gonzalez, AE, Martin-Broto, J, Marin, VM, Vega, AM, Garcia, AS, Morales, CV
Publicada:
1 may 2021
Ahead of Print:
1 ene 2021
Resumen:
Soft-tissue sarcomas constitute an uncommon and heterogeneous group of tumors of mesenchymal origin. Diagnosis, treatment, and management should be performed by an expert multidisciplinary team. MRI/CT of the primary tumor and biopsy is mandatory before any treatment. Wide surgical resection with tumor-free tissue margin is the mainstay for localized disease. Radiotherapy is indicated in large, deep, high-grade tumors, or after marginal resection not suitable for re-excision. Perioperative chemotherapy should be discussed for high-risk sarcomas of the extremities and trunk-wall. In the case of oligometastatic disease, patients should be considered for local therapies. First-line treatment with anthracyclines (or in combination with ifosfamide) is the treatment of choice. Other drugs have shown activity in second-line therapy and in specific histological subtypes but options are limited and thus, a clinical trial should always be discussed.
Filiaciones:
Ferre, AD:
Hosp Univ Marques Valdecilla, Santander, Spain
Alvarez, RA:
Hosp Gen Univ Gregorio Maranon, Madrid, Spain
Herraez, AC:
Hosp Univ Clin San Carlos, Madrid, Spain
Jurado, JC:
Hosp Univ Canarias, Tenerife, Spain
Gonzalez, AE:
Inst Catala Oncol Badalona, Barcelona, Spain
Martin-Broto, J:
Hosp Univ Virgen Rocio, Seville, Spain
Marin, VM:
Hosp Univ La Paz, Madrid, Spain
Vega, AM:
Hosp Univ Reina Sofia, Cordoba, Spain
Garcia, AS:
Hosp Santa Creu & Sant Pau, Barcelona, Spain
Morales, CV:
Hosp Univ Vall dHebron, Barcelona, Spain
Green Published, hybrid
|